Bode John B 4

What Happened
John Bode, a director of Zevra Therapeutics (ZVRA), exercised stock options on March 24, 2026 to acquire a total of 78,400 common shares. He acquired 39,200 shares at $4.97 per share ($194,824) and another 39,200 shares at $4.89 per share ($191,688), for a combined cash outlay of $386,512. The filing also shows corresponding disposals of the underlying derivative securities (the options) at $0.00, which reflects cancellation/conversion of those option awards upon exercise.

Key Details

• Transaction date: 2026-03-24 (Form 4 filed 2026-03-26; appears timely).
• Shares acquired: 39,200 @ $4.97 (total $194,824) and 39,200 @ $4.89 (total $191,688); total acquired = 78,400 shares for $386,512.
• Derivative disposed: two entries of 39,200 shares each at $0.00 (these represent the option(s) converted/cancelled on exercise).
• Shares owned after transaction: Not specified in the supplied summary—see the full Form 4 for post-transaction holdings.
• Footnotes:
  • F1: Remaining shares under the May 3, 2023 option will vest one day prior to the date of the third annual meeting after the grant, subject to continued service.
  • F2: Shares underlying the May 13, 2024 option were fully vested.
• No indication in this filing that the shares were immediately sold (no open-market sale reported).

Context
This was an option exercise (transaction code M): the insider converted option rights into common shares and paid the exercise price. Such exercises can be routine (e.g., to take ownership of vested shares or for planning/tax reasons) and do not by themselves indicate buy/sell sentiment. For exact post-exercise holdings and any related tax withholding or share transfers, review the complete Form 4 on the SEC EDGAR system.